New hope for patients with rare, Hard-to-Treat blood disorders
NCT ID NCT03801434
Summary
This study is testing whether the drug ruxolitinib can help control rare blood disorders where the body makes too many eosinophils, a type of white blood cell. It will involve about 10 adults whose conditions have not responded well to standard treatments like steroids. The main goal is to see if the drug can lower eosinophil counts, reduce symptoms, and help patients use less steroid medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPEREOSINOPHILIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutchinson cancer research center
TERMINATEDSeattle, Washington, 98109, United States
-
OHSU Knight Cancer Institute
TERMINATEDPortland, Oregon, 97201, United States
-
Stanford Cancer Institute Palo Alto
RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Utah
TERMINATEDSalt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.